Aurobindo Pharma Limited

Plot No.# 2

Maitri Vihar, Ameerpet

500038 Hyderabad , India

To be linked to this company


Manufacturers and Exporters of some of the most quality conscious Active Pharmaceutical Ingredients (bulk actives), intermediates, Peptides and speciality generic formulations.
Manufactures of semi synthetic penicillins and cephalosporins.
Manufacturer of Bulk Drugs, Intermediates & Formulations such as Antibiotic Penicillins, Antibiotic Cephalosporins, Anti - Microbials, Anti - Microbials - Quinolones, Macrolides, Sunfonamides, Antiprotozoals, Cardiovasculars, Anti Ashthmatics, Anti Fungals, Sterile - Parenterals, Fluroquinolo
Product Profile:
ANTI-DEPRESSANTS: Citalopram HBr, Bupropion HCl, Fluoxetine HCl,Gabapentin, Melitracin HCl, Mirtazapine, Paroxetine HCl, Risperidone, Sertraline HCl.
ANTI-CONVULSANTS- Leviteracetam,Topiramate.
HYPNOTICS & ANTI-PSYCHOTICS-Flupenthixol,Olanzapine,Zolpidem,Quetiapine,Zaleplon.
ANTI-HYPERTENSIVES-Benazepril, Fosinopril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandolapril, Losartan Potassium.
BETA BLOCKERS- Bisoprolol Fumarate, Carvedilol.
THIAZIDE DIURETIC- Hydrochlorothiazide.
ANTI-THROMBOTIC - Clopidogrel bisulfate, Pentoxifylline.
STATINS- Atorvastatin Calcium, Fluvastatin, Simvastatin.
ANTI-DIABETICS- Gilbenclamide, Metformin HCL.
BPH-TREATMENT- Finasteride, Tamsulosin.
ANTI-EMETICS - Domperidone Base/Maleate, Ondansetron HCL.
ANTI-ULCERANTS - Lansoprazole Powder/Pellets, Omeprazole Powder/Pellets, Pantoprazole Sodium, Rabeprazole Sodium.
ANTI-RETROVIRALS- Abacavir, Didanosine, Efavirenz, Indinavir, Lamivudine, Lopinavir, Nelfinavir, Mesylate, Nevirapine, Ritonavir,
Saquinavir, Stavudine , Zidovudine .
ANTI-VIRALS - Ribavirin.
MACROLIDES- Azithromycin Monohydrate.
ANTI-FUNGALS - Fluconazole, Terbinafine HCl.
QUINOLONES- Ciprofloxacin HCL, Moxifloxacin
ANTI-HISTAMINES - Fexofenadine
ANTI-OSTEOPOROSIS -Alendronate Sodium

General Information

Year Established: 1986

www :

Type of company : Headquarters


Type:ISO 9001





Import/export regions

Import regions :
Export regions :
  • Worldwide
  • Asia-Pacific
  • South America
  • Western Europe
  • Africa
  • North America
  • Central/East Europe


On site
Total group


2012 : 46,520,000,000 INR


P = Producer / D = Distributor / S = Service


This company has not added any products


K. Ragunathan

Independent Director & Non-Executive Chairman

K. Nityananda Reddy

Wholetime Director & Vice Chairman

P. V. Ramaprasad Reddy

Non-Executive Director

N. Govindarajan


M. Madan Mohan Reddy

Whole Time Director

M. Sivaram Kumaran

Wholetime Director

M. Sitarama Murthy

Independent Director

D. Rajagopala Redddy

Independent Director

C. Channa Reddy

Independent Director

P. Sarath Chandra Reddy

Non-Executive Director

A. Mohan Rami Reddy

General Manager (Legal)

Sudhir Singhi

Chief Finance Officer

P. Sashikumar

Purchase Head


Aurobindo Pharma acquires Actavis operations in 7 European countries

Aurobindo Pharma acquires Actavis operations in 7 European countries

Published on {0}

Hyderabad: Aurobindo Pharma Ltd has completed the acquisition of certain commercial operations in Western Europe from Actavis Plc. In January this year, the Hyderabad-based Aurobindo Pharma had signed an agreement with Actavis to acquire its personnel, commercial infrastructure, products, marketing authorisations and dossier licence rights in seven European countries for €30 million.

Both companies had also inked a long-term commercial and supply arrangement.

“The acquisition will make Aurobindo one of the leading Indian pharmaceutical companies in Europe with a top 10 position in several key markets,’’ Muralidharan, Senior Vice-President of European operations for Aurobindo, said here on Tuesday.

Smooth transition

Aurobindo would work to combine the strength of both enterprises in these markets and to identify and maximise all opportunities.

“We will continue to collaborate with Actavis to ensure business continuity and a smooth transition. In parallel, we will work closely with the acquired management teams to achieve a rapid and successful integration,’’ he added. Aurobindo’s scrip gained 4.67 per cent on BSE on Tuesday to end at Rs. 534.70.

Disclaimer: Orignal source from IBEF